The Present And Emerging Investigational Drugs For Chronic Hepatitis C: Current Status

R. Kumar
{"title":"The Present And Emerging Investigational Drugs For Chronic Hepatitis C: Current Status","authors":"R. Kumar","doi":"10.5580/1a5e","DOIUrl":null,"url":null,"abstract":"Chronic hepatitis C is caused by flavi virus (RNA virus) and is the leading cause for cirrhosis, hepatocellular carcinoma and liver transplantation. The standard therapy of chronic hepatitis C is peg interferon α weekly plus oral-ribavirin daily is not effective in all patients and is limited by adverse effect. Therefore new investigational drugs are being developed and in pipeline. This article focuses on new investigational drugs that are presently in an advance stage of development also focuses on newer interferons, ribavirin analogue and anti apoptotic drug.","PeriodicalId":22523,"journal":{"name":"The Internet Journal of Pharmacology","volume":"37 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2008-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Internet Journal of Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5580/1a5e","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Chronic hepatitis C is caused by flavi virus (RNA virus) and is the leading cause for cirrhosis, hepatocellular carcinoma and liver transplantation. The standard therapy of chronic hepatitis C is peg interferon α weekly plus oral-ribavirin daily is not effective in all patients and is limited by adverse effect. Therefore new investigational drugs are being developed and in pipeline. This article focuses on new investigational drugs that are presently in an advance stage of development also focuses on newer interferons, ribavirin analogue and anti apoptotic drug.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
慢性丙型肝炎的现有和新兴研究药物:现状
慢性丙型肝炎是由黄病毒(RNA病毒)引起的,是肝硬化、肝细胞癌和肝移植的主要原因。慢性丙型肝炎的标准治疗是每周一次聚乙二醇干扰素加每日口服利巴韦林,但并非对所有患者都有效,并且受到不良反应的限制。因此,新的研究药物正在开发和准备中。本文重点介绍了目前处于研发前期的新研究药物,以及较新的干扰素、利巴韦林类似物和抗凋亡药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Acute And Subacute Toxicity Of Aqueous Extract Of Abrus Precatorius Seed In Wister Rats Artemisinin Combination Therapies; Safe Or Not Safe ? An Antibacterial Drug Utilization Study at Surgical Units of Shree Sayaji General Hospital, Vadodara, Gujarat, India Rational Use of Drugs and Irrational Drug Combinations Evaluation Of Antiulcer Activity Of Ocimum Sanctum And Its Mechanism In Animal Models
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1